CRBU Q3 2022 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$181M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-16.9% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$27M-803.4% margin

Net Income

-$27M-806.8% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

-21.2%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$24M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$399M

Total Liabilities

$75M

Stockholders' Equity

$324M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-16.9%
Gross Profit	$3M	-$12M	+127.9%
Operating Income	-$27M	-$19M	-42.5%
Net Income	-$27M	-$21M	-27.0%

Geographic Segments

UNITED STATES

$3M90%

Non-US

$337,00010%